Log in

NASDAQ:ILMN - Illumina Stock Price, Forecast & News

$324.72
-1.24 (-0.38 %)
(As of 01/19/2020 11:12 AM ET)
Add
Compare
Today's Range
$320.46
Now: $324.72▼
$327.93
50-Day Range
$317.11
MA: $326.92▼
$335.63
52-Week Range
$263.30
Now: $324.72▼
$380.76
Volume1.11 million shs
Average Volume919,105 shs
Market Capitalization$47.73 billion
P/E Ratio49.58
Dividend YieldN/A
Beta1.05
Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array. Read More…

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Analytical instruments
Sub-IndustryLife Sciences Tools & Services
SectorMedical
Current SymbolNASDAQ:ILMN
Previous Symbol
CUSIP45232710
CIK1110803
Webhttp://www.illumina.com/
Phone858-202-4500

Debt

Debt-to-Equity Ratio0.41
Current Ratio6.82
Quick Ratio6.15

Price-To-Earnings

Trailing P/E Ratio49.58
Forward P/E Ratio50.27
P/E Growth2.24

Sales & Book Value

Annual Sales$3.33 billion
Price / Sales14.32
Cash Flow$7.25 per share
Price / Cash Flow44.79
Book Value$26.16 per share
Price / Book12.41

Profitability

EPS (Most Recent Fiscal Year)$5.72
Net Income$826 million
Net Margins28.14%
Return on Equity22.05%
Return on Assets12.95%

Miscellaneous

Employees7,300
Outstanding Shares147,000,000
Market Cap$47.73 billion
Next Earnings Date1/29/2020 (Confirmed)
OptionableOptionable

Receive ILMN News and Ratings via Email

Sign-up to receive the latest news and ratings for ILMN and its competitors with MarketBeat's FREE daily newsletter.

NASDAQ:ILMN Rates by TradingView

(Ad)


What a cool story coming out of The War Room today.

One of the members made a trade on Bryan's recommendation... went to get a cup of coffee... and closed out a 33% win by the time he got back!

That's more than most people make in a year! You CANNOT miss out on these wins anymore.

Illumina (NASDAQ:ILMN) Frequently Asked Questions

What is Illumina's stock symbol?

Illumina trades on the NASDAQ under the ticker symbol "ILMN."

How were Illumina's earnings last quarter?

Illumina, Inc. (NASDAQ:ILMN) posted its earnings results on Thursday, October, 24th. The life sciences company reported $1.93 earnings per share for the quarter, topping analysts' consensus estimates of $1.40 by $0.53. The life sciences company had revenue of $907 million for the quarter, compared to analysts' expectations of $872.65 million. Illumina had a net margin of 28.14% and a return on equity of 22.05%. The company's revenue was up 6.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.52 earnings per share. View Illumina's Earnings History.

When is Illumina's next earnings date?

Illumina is scheduled to release their next quarterly earnings announcement on Wednesday, January 29th 2020. View Earnings Estimates for Illumina.

How can I listen to Illumina's earnings call?

Illumina will be holding an earnings conference call on Wednesday, January 29th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

What guidance has Illumina issued on next quarter's earnings?

Illumina updated its fourth quarter 2019 After-Hours earnings guidance on Monday, January, 13th. The company provided EPS guidance of for the period. The company issued revenue guidance of $950-950 million, compared to the consensus revenue estimate of $939.29 million.

What price target have analysts set for ILMN?

16 analysts have issued 12-month price targets for Illumina's shares. Their forecasts range from $280.00 to $385.00. On average, they expect Illumina's share price to reach $339.73 in the next year. This suggests a possible upside of 4.6% from the stock's current price. View Analyst Price Targets for Illumina.

What is the consensus analysts' recommendation for Illumina?

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Illumina in the last year. There are currently 2 sell ratings, 2 hold ratings and 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Illumina.

What are Wall Street analysts saying about Illumina stock?

Here are some recent quotes from research analysts about Illumina stock:
  • 1. Canaccord Genuity analysts commented, "We don’t believe an ultra-premium multiple is now justified for a company looking to grow +6% on the top and bottom lines, which now seem more vulnerable to large misses. What’s more, we lack visibility to 2020 or 2021 growth rates given a wide range of moving parts. We would look to get more constructive if our concerns prove to be transitory, or if ILMN announces the $100 genome at a price point that would meaningfully accelerate its top line and not add further headwinds to its gross, operating or net income margins. ILMN is working hard to drive down the cost of sequencing to be able to usher in the eagerly awaited $100 genome. DTC troubles. On the call, Illumina CEO Francis deSouza indicated he expects a DTC reacceleration “in the coming years,” which to us doesn’t imply a recovery in 2020." (7/30/2019)
  • 2. According to Zacks Investment Research, "Illumina continues to register strong top line growth across the company’s high throughput, mid throughput and low throughput categories. In the last-reported fourth quarter, the company observed strong demand for sequencing and array systems, consumables and services. Meanwhile HiSeq to NovaSeq upgrade cycle is progressing well and NextSeq placements are strong. We are also looking forward to the company's newly-inked Pacific Biosciences deal. In the past year, Illumina has outperformed its industry. However, we note that, Illumina exited the fourth quarter of 2018 on a mixed note with earnings lagging the Zacks Consensus Estimate. HiSeq consumables are continuing with their expected decline. Seasonality in DTC functionality continues to dent Illumina’s microarray sales. Funding issues restrict growth. The company is operating in a tough competitive landscape." (4/2/2019)

Has Illumina been receiving favorable news coverage?

Headlines about ILMN stock have trended positive recently, InfoTrie Sentiment reports. InfoTrie ranks the sentiment of press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Illumina earned a news impact score of 2.2 on InfoTrie's scale. They also assigned headlines about the life sciences company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View News Stories for Illumina.

Are investors shorting Illumina?

Illumina saw a increase in short interest in the month of December. As of December 31st, there was short interest totalling 3,610,000 shares, an increase of 8.4% from the December 15th total of 3,330,000 shares. Based on an average daily volume of 868,000 shares, the short-interest ratio is currently 4.2 days. Approximately 2.5% of the company's stock are short sold. View Illumina's Current Options Chain.

Who are some of Illumina's key competitors?

What other stocks do shareholders of Illumina own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Illumina investors own include NVIDIA (NVDA), Netflix (NFLX), Alibaba Group (BABA), Walt Disney (DIS), Visa (V), Baidu (BIDU), Adobe (ADBE), Tesla (TSLA), Micron Technology (MU) and Paypal (PYPL).

Who are Illumina's key executives?

Illumina's management team includes the folowing people:
  • Mr. Jay T. Flatley, Exec. Chairman (Age 66)
  • Mr. Francis A. deSouza, CEO, Pres & Director (Age 48)
  • Mr. Sam A. Samad, CFO & Sr. VP (Age 49)
  • Mr. Omead Ostadan, Sr. VP of Products, Marketing & Strategic Planning (Age 47)
  • Ms. Aimee L. Hoyt, Chief People Officer & Sr. VP (Age 48)

Who are Illumina's major shareholders?

Illumina's stock is owned by a number of of retail and institutional investors. Top institutional investors include Peregrine Capital Management LLC (0.06%), Gateway Investment Advisers LLC (0.05%), Copper Rock Capital Partners LLC (0.03%), Assenagon Asset Management S.A. (0.03%), Capital Investment Services of America Inc. (0.03%) and Hemenway Trust Co LLC (0.03%). Company insiders that own Illumina stock include A Blaine Bowman, Aimee L Hoyt, Charles Dadswell, Frances Arnold, Francis A Desouza, Jay T Flatley, Karin Eastham, Marc Stapley, Mostafa Ronaghi, Oene Mark Van, Omead Ostadan, Phillip G Febbo, Robert P Ragusa, Robert S Epstein, Sam Samad and Susan H Tousi. View Institutional Ownership Trends for Illumina.

Which institutional investors are selling Illumina stock?

ILMN stock was sold by a variety of institutional investors in the last quarter, including First Hawaiian Bank, Spence Asset Management, Meag Munich Ergo Kapitalanlagegesellschaft MBH, Gateway Investment Advisers LLC, Anderson Hoagland & Co., State of Alaska Department of Revenue, Nisa Investment Advisors LLC and Arthur M. Cohen & Associates LLC. Company insiders that have sold Illumina company stock in the last year include Aimee L Hoyt, Charles Dadswell, Frances Arnold, Francis A Desouza, Jay T Flatley, Mostafa Ronaghi, Oene Mark Van, Omead Ostadan, Phillip G Febbo, Robert P Ragusa, Robert S Epstein, Sam Samad and Susan H Tousi. View Insider Buying and Selling for Illumina.

Which institutional investors are buying Illumina stock?

ILMN stock was acquired by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Capital Investment Services of America Inc., Vigilant Capital Management LLC, Alpine Global Management LLC, Farmers Trust Co., Baxter Bros Inc., West Oak Capital LLC and DNB Asset Management AS. View Insider Buying and Selling for Illumina.

How do I buy shares of Illumina?

Shares of ILMN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Illumina's stock price today?

One share of ILMN stock can currently be purchased for approximately $324.72.

How big of a company is Illumina?

Illumina has a market capitalization of $47.73 billion and generates $3.33 billion in revenue each year. The life sciences company earns $826 million in net income (profit) each year or $5.72 on an earnings per share basis. Illumina employs 7,300 workers across the globe.View Additional Information About Illumina.

What is Illumina's official website?

The official website for Illumina is http://www.illumina.com/.

How can I contact Illumina?

Illumina's mailing address is 5200 ILLUMINA WAY, SAN DIEGO CA, 92122. The life sciences company can be reached via phone at 858-202-4500 or via email at [email protected]


MarketBeat Community Rating for Illumina (NASDAQ ILMN)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  978 (Vote Outperform)
Underperform Votes:  870 (Vote Underperform)
Total Votes:  1,848
MarketBeat's community ratings are surveys of what our community members think about Illumina and other stocks. Vote "Outperform" if you believe ILMN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ILMN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/19/2020 by MarketBeat.com Staff

Featured Article: P/E Growth (PEG)
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel